{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-297530","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2022-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.894656+00:00","generated_at":"2026-06-21T10:12:53.823302+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Karyopharm amends bylaws for universal proxy rules and meeting procedures","bullets":["Eliminated requirement to make stockholder list available during meetings.","Addressed adjournment of stockholder meetings due to technical failure in remote communication.","Enhanced disclosure and representation requirements for shareholder nominations under universal proxy rules.","Requires stockholders soliciting proxies to provide evidence of Rule 14a-19 compliance five business days before meeting.","Non-compliance with Rule 14a-19 will cause Company to disregard nominations and votes for those nominees."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-297530","json":"https://secwatch.observer/filing/0001193125-22-297530.json","markdown":"https://secwatch.observer/filing/0001193125-22-297530.md","text":"https://secwatch.observer/filing/0001193125-22-297530.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312522297530/0001193125-22-297530-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312522297530/d423713d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T10:12:53.823302+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cb315418e99a1784f9e263ec750ec820f25f6173","claim":"Karyopharm Therapeutics Inc.: The Board approved and restated the Third Amended and Restated By-Laws, effective immediately, with amendments including elimination of stockholder list requirement during meetings, addressing remote meeting adjournment due to technical failure, and revising procedural mechanics for shareholder nomi (effective 2022-12-01).","evidence_excerpt":"On December 1, 2022, the board of directors (the “Board”) of Karyopharm Therapeutics Inc. (the “Company”) approved an amendment and restatement of the Company’s Second Amended and Restated By-Laws, as amended (as so amended and restated, the “Third Amended and Restated By-Laws”), effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312522297530/0001193125-22-297530-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2022-12-01"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}